Chronic Myeloid Leukemia Epidemiology Forecast 2026-2035

Read more about this report - Request a Free Sample

Chronic Myeloid Leukemia Epidemiology Forecast Report Coverage

Expert Market Research's “Chronic Myeloid Leukemia Epidemiology Forecast Report 2026-2035” offers comprehensive information on the prevalence and demographics of chronic myeloid leukemia. It projects the future incidence and prevalence rates of chronic myeloid leukemia cases across various populations. The study covers age, gender, and type as major determinants of the chronic myeloid leukemia population. The report highlights patterns in the prevalence of chronic myeloid leukemia over time and projects future trends based on multiple variables.

Chronic Myeloid Leukemia Understanding: Disease Overview

Chronic myeloid leukemia (CML) is a myeloproliferative neoplasm caused by the BCR-ABL1 fusion gene, resulting from the Philadelphia chromosome translocation t(9;22). The disease progresses through chronic, accelerated, and blast crisis phases, with most patients diagnosed in the chronic phase. CML primarily affects adults aged 50-60 years. Diagnosis relies on molecular detection of BCR-ABL1 using PCR or FISH testing. Without treatment, CML evolves into an acute leukemia-like phase, but early detection allows long-term disease control with modern therapies.

Chronic Myeloid Leukemia Epidemiology Perspective

The chronic myeloid leukemia epidemiology division offers information on the patient pool from history to the present, as well as the projected trend for each of the 8 major markets. Expert Market Research provides both current and predicted trends for the chronic myeloid leukemia epidemiology scenario by examining a wide range of studies. Additionally, the report covers the diagnosed patient pool for chronic myeloid leukemia and their trends. The chronic myeloid leukemia detailed epidemiology segmentation is broken down into specific categories, such as total prevalent cases in males and females, and total diagnosed cases across different age groups and patient pools.

• In many developed countries, the reported annual incidence of CML is approximately 1 to 2 cases per 100,000 persons.
• In developing countries, median age appears somewhat lower (for example ~40–50 years in some Indian data). There is a slight male predominance (around ~1.4:1).
• Chronic myeloid leukemia (CML) typically impacts middle-aged and older adults and having a family history of hematological disorders may slightly elevate the risk.
• Incidence, death rates, and disability-adjusted life years (DALYs) for CML have shown declines in higher-SDI (socio-demographic index) countries over the past decades, but rising absolute case counts in lower-SDI countries (largely due to population growth and ageing).

Read more about this report - Request a Free Sample

Country-wise Chronic Myeloid Leukemia Epidemiology Segment

The chronic myeloid leukemia epidemiology data and findings for the United States, Germany, Spain, Italy, France, the United Kingdom, Japan, and India are also provided in the epidemiology section.

In the United States, chronic myeloid leukemia (CML) remains a relatively rare hematologic malignancy, with an estimated 9,280 new cases projected in 2024. According to national cancer registry data, the age-adjusted incidence rate is approximately 2.0 per 100,000 persons annually, reflecting stable trends over the past decade. CML primarily affects middle-aged and older adults, with incidence increasing steadily with age. Epidemiological studies consistently show a slight male predominance, with men experiencing higher rates than women.

Chronic Myeloid Leukemia: Treatment Overview

The treatment for CML centers on targeted inhibition of the BCR-ABL1 tyrosine kinase. First-line therapies include tyrosine kinase inhibitors (TKIs) such as imatinib, dasatinib, and nilotinib, which have transformed survival outcomes. Second- and third-generation TKIs (bosutinib, ponatinib) are used for resistant mutations, including T315I. Molecular monitoring through quantitative PCR guides therapy adjustments and identifies deep molecular responses. Allogeneic stem-cell transplantation is reserved for refractory or advanced-phase disease. Lifelong therapy adherence and monitoring are crucial to maintain remission and prevent relapse.

Key Questions Answered

• What are the key findings of chronic myeloid leukemia epidemiology in the 8 major markets?
• What will be the total number of patients with chronic myeloid leukemia across the 8 major markets during the forecast period?
• What was the country-wise chronic myeloid leukemia epidemiology scenario in the 8 major markets in the historical period?
• Which country will have the highest number of cases of chronic myeloid leukemia during the forecast period of 2026-2035?
• Which key factors would influence the shift in the patient population of chronic myeloid leukemia during the forecast period of 2026-2035?
• What are the currently available treatments for chronic myeloid leukemia?
• What are the disease risks, signs, symptoms, and unmet needs of chronic myeloid leukemia?

Scope of the Chronic Myeloid Leukemia Epidemiology Report

• The report covers a detailed analysis of signs and symptoms, causes, risk factors, pathophysiology, diagnosis, treatment options, and classification/types of chronic myeloid leukemia based on several factors.
• Chronic Myeloid Leukemia Epidemiology Forecast Report covers data for the eight major markets (the US, France, Germany, Italy, Spain, the UK, Japan, and India).
• The chronic myeloid leukemia report helps to identify the patient population, and the unmet needs are highlighted along with an assessment of the disease's risk and burden.

Related Reports

Relapsed/Refractory Acute Myeloid Leukemia Pipeline Analysis

Acute Myeloid Leukemia Treatment Market